TY - JOUR
T1 - Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis
T2 - 5-year data from the DIVA study long-term extension
AU - Bianchi, G.
AU - Czerwinski, E.
AU - Kenwright, A.
AU - Burdeska, A.
AU - Recker, R. R.
AU - Felsenberg, D.
N1 - Funding Information:
Dr. Bianchi has received honoraria and/or consulting fees from Abbott, Amgen, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Schering Plough, and Servier. Dr. Czerwinski has received research grants from Amgen, Eli Lilly, Merck, Novartis, Pfizer, Procter and Gamble, Roche, and Servier. Dr. Recker is a paid consultant for Merck, Lilly, Pfizer, Procter and Gamble, Amgen, Roche, Glaxo Smith Kline, and Novartis and has received grant/research support from Merck, Lilly, Wyeth, Procter and Gamble, Amgen, Roche, Glaxo Smith Kline, Novartis, and Sanofi-Aventis through grants to his institution. Dr. Felsenberg serves as a consultant for Amgen, Chugai, GlaxoSmithKline, Lilly, Merck, Novartis, Roche, and Servier. Dr. Burdeska and Dr. Kenwright are employees of F. Hoffmann-La Roche; Dr Kenwright has some shares in this company.
Funding Information:
The DIVA study LTE was funded by F. Hoffmann-La Roche and GlaxoSmithKline.
PY - 2012/6
Y1 - 2012/6
N2 - Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4% [95% confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.
AB - Summary Long-term bone mineral density (BMD) gains, bone marker levels, and safety of 3 mg quarterly intravenous (IV) ibandronate were studied in this 3-year extension to the Dosing IntraVenous Administration (DIVA) trial. Quarterly IV ibandronate consistently increased lumbar spine bone mineral density measured with dual-energy X-ray absorptiometry (DXA-BMD) over 5 years (8.1%) and was well tolerated in women with postmenopausal osteoporosis. Introduction Treatment with IV ibandronate regimens, 2 mg bimonthly and 3 mg quarterly, has been studied for up to 5 years in a long-termextension (LTE) to the 2-year DIVAtrial. Methods DIVA LTE is an open-label extension to a 2-year randomized, double-blind, double-dummy, noninferiority, phase III study (DIVA core). DIVA LTE involved postmenopausal women who had completed 2 years of DIVA core, comparing daily oral and IV ibandronate (≫75% adherence with IV ibandronate in year 2 of DIVA). Patients previously treated with 2 mg bimonthly or 3 mg quarterly IV ibandronate continued on the same regimen; patients who had received 2.5 mg daily oral ibandronate and placebo IV in DIVA core were switched to IV ibandronate. Results Pooled analysis of 497 intent-to-treat (ITT) patients receiving IV ibandronate from DIVA core baseline showed consistent increases over 5 years in lumbar spine DXABMD (8.4% [95% confidence interval (CI)=7.5, 9.3] with 2 mg bimonthly and 8.1% [95% CI=7.2, 8.9] with 3 mg quarterly). Three-year data relative to DIVA LTE baseline in the full ITT population (756 patients randomized or reallocated from DIVA, including those previously on daily treatment) showed maintenance of DXA-BMD gains from DIVA core with further gains in lumbar spine DXA-BMD. These benefits are supported by sustained reductions in markers of bone metabolism. No tolerability concerns or new safety signals were observed. Conclusions Treatment with IV ibandronate 2 mg bimonthly or 3 mg quarterly is effective and well tolerated for up to 5 years in women with postmenopausal osteoporosis.
UR - http://www.scopus.com/inward/record.url?scp=84863617923&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863617923&partnerID=8YFLogxK
U2 - 10.1007/s00198-011-1793-9
DO - 10.1007/s00198-011-1793-9
M3 - Article
C2 - 21975558
AN - SCOPUS:84863617923
VL - 23
SP - 1769
EP - 1778
JO - Osteoporosis International
JF - Osteoporosis International
SN - 0937-941X
IS - 6
ER -